SanReno Therapeutics, a China-based joint venture (JV) specializing in nephropathy treatments, has announced the completion of dosing in 36 patients for its new kidney disease drug, BION-1301, in a trial conducted in Shanghai. The JV is a collaboration between Chinook Therapeutics Inc., a US-based biopharmaceutical company listed on Nasdaq (KDNY), and investors Frazier Healthcare Partners and Pivotal bioVenture Partners China.
BION-1301: A Promising Treatment for IgA Nephropathy
BION-1301 is an anti-APRIL monoclonal antibody under development for the treatment of IgA nephropathy (IgAN). This innovative drug works by reducing the production of pathogenic galactose-deficient immunoglobulin A1 (Gd IgA1), which may alter the disease’s progression. Additionally, BION-1301 is designed to minimize impacts on IgG and immature lymphocyte populations, thereby avoiding broad immune suppression and reducing the potential risk of infection.
Strategic JV Agreement and Pipeline Enhancement
Under the terms of the joint venture agreement, Chinook contributed two of its lead pipeline candidates, atrasentan and BION-1301, to SanReno in return for a 50% ownership stake in the JV. This strategic move enhances SanReno’s pipeline and positions the company to make significant advancements in the treatment of kidney diseases, particularly IgAN.-Fineline Info & Tech
